Announcements, product catalog expansions, certifications, and company updates from Drug Logix India.
Catalog Launch
The updated 2026 catalog adds reference standards covering Acebutolol, Aripiprazole, Bortezomib, Cinnarizine, Fluphenazine HCl and Ziprasidone — alongside dozens more end-use APIs. Every product is backed by ¹H-NMR, HPLC, MS and full Certificate of Analysis, ICH Q3A/Q3B-compliant, and ready for regulatory submissions.
Browse Catalog
Product Launch
Our expanded Intermediates catalog covers Acalabrutinib, Dabigatran, Solifenacin, Luliconazole, Voriconazole and more — produced under ICH Q7 GMP guidance with full analytical characterisation.
See Intermediates
Capability
In response to tightening global regulatory guidance on nitrosamines and nitrosamine-drug substance-related impurities (NDSRIs), Drug Logix India has opened a dedicated high-security synthesis unit for trace-level nitrosamine standards.
Learn More
New Vertical
Drug Logix India's new agrochemical vertical launches with Pyriproxyfen, Cymoxanil, Clodinafop Propargyl, and Bispyribac-sodium — supporting method development, residue analysis and regulatory compliance for crop-protection R&D labs.
See Catalog
Certification
The successful certification audit validates our quality management system end-to-end — from raw material intake to Certificate of Analysis issuance — aligning our workflows with international best practice.
About Our QMS
Milestone
Founded by Hari Babu Matta with Co-founder T. Parvathi and Director Dr. Surya Raguthu, Drug Logix India launches as a chemical research-based pharmaceutical company focused on API impurities, intermediates and custom synthesis — bringing together a team with 50+ years of combined industry experience.
Our Story
Partnership
Drug Logix India has been selected as a preferred impurity synthesis and analytical development partner — a three-year engagement covering 40+ APIs across cardiovascular, CNS and oncology therapeutic areas.
CRO Services
Conference
Hari Babu Matta, Founder of Drug Logix India, delivered a technical session on the synthesis and characterisation of genotoxic impurities and NDSRIs at CPhI India, Hyderabad — drawing participation from 100+ pharma R&D professionals.
Get in Touch